Follow
Turki Althunian
Turki Althunian
Saudi Food and Drug Authority
No verified email
Title
Cited by
Cited by
Year
Defining the noninferiority margin and analysing noninferiority: an overview
TA Althunian, A de Boer, RHH Groenwold, OH Klungel
British journal of clinical pharmacology 83 (8), 1636-1642, 2017
1082017
Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review
TA Althunian, A de Boer, OH Klungel, WN Insani, RHH Groenwold
Trials 18 (1), 1-9, 2017
552017
Analyzing the US Post-marketing safety surveillance of COVID-19 vaccines
OM Albalawi, MI Alomran, GM Alsagri, TA Althunian, TM Alshammari
Saudi Pharmaceutical Journal 30 (2), 180-184, 2022
42022
Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate
TA Althunian, A de Boer, RHH Groenwold, OH Klungel
Journal of Clinical Epidemiology 104, 15-23, 2018
32018
Effectiveness of topical vancomycin in the prevention of spinal surgical site infections: a retrospective cohort study
RT Tafish, AF Alkhaldi, A Bourghli, TA Althunian
Antimicrobial Resistance & Infection Control 10 (1), 1-8, 2021
12021
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study
TA Althunian, A de Boer, RHH Groenwold, KO Rengerink, PC Souverein, ...
Pharmacoepidemiology and Drug Safety 29 (10), 1263-1272, 2020
12020
Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins
TA Althunian, A de Boer, AK Mantel-Teeuwisse, RHH Groenwold, ...
Clinical Therapeutics 42 (8), 1588-1594, 2020
12020
Replication of rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation in …
TAI Althunian, A De Boer, RHH Groenwold, KO Rengerink, PC Souverein, ...
Pharmacoepidemiology and Drug Safety 28 (S2), 57, 2019
12019
Validating the standardized and ICD-9 code of type 2 diabetes mellitus in a Saudi common data model
TAI Althunian, M Alrasheed, F Alnofal, R Tafish, MA Mira, RA Alroba, ...
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 451-451, 2022
2022
The impact of regulatory restrictions on pregabalin use in Saudi Arabia: An interrupted time series analysis
TA Althunian, MI Alomran, GM Alsagri, MM Alrasheed, TM Alshammari
Pharmacoepidemiology and Drug Safety 31 (5), 577-582, 2022
2022
The impact of regulatory restrictions on the use of pregabalin: An interrupted time-series
TA Althunian, M Alomran, G Alsagri, M Alrasheed, TM Alshammari
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 360-360, 2021
2021
Oral Presentation: Analyzing the US Post-Marketing Safety Surveillance of COVID-19 Vaccines: An International Journal of Medical Toxicology and Drug Experience
O Albalawi, M Alomran, G Alsagri, T Althunian, T Alshammari
Drug Safety, 1395-1396, 2021
2021
Non-inferiority studies: a methodological and regulatory perspective
TAI Althunian
Utrecht University, 2019
2019
Regulatory challenges in the design of non-inferiority trials: Evaluating scientific advice letters from the European Medicines Agency (EMA)
T Althunian, A De Boer, AK Mantel-Teeuwisse, RHH Groenwold, GD Wied, ...
Pharmacoepidemiology and Drug Safety 27 (S2), 2018
2018
Using a single non-inferiority margin or a single preserved fraction for an entire pharmacological class may be invalid for the analysis of non-inferiority: A case study of …
T Althunian, A De Boer, RHH Groenwold, OH Klungel
Pharmacoepidemiology and Drug Safety 27 (S2), 2018
2018
Methods of Defining the Noninferiority Margin: A Systematic Review
TAI Althunian, A de Boer, OH Klungel, WN Insani, RHH Groenwold
Pharmacoepidemiology and Drug Safety 25 (Suppl. S3), 139-140, 2016
2016
The system can't perform the operation now. Try again later.
Articles 1–16